Methods for enhancing the potency of the immune checkpoint inhibitors

Patent metadata

Field	Value
Publication number	US-10822415-B2
Application number	US-201716073080-A
Country	US
Kind code	B2
Filing date	Jan 27, 2017
Priority date	Jan 28, 2016
Publication date	Nov 3, 2020
Grant date	Nov 3, 2020

Abstract

The present invention relates to methods for enhancing the potency of the immune checkpoint inhibitors. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen, the method comprising administering a pharmaceutically effective amount of a SK1 inhibitor to a subject in combination with the immune checkpoint inhibitor.

First claim

The invention claimed is:

1. A method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen, the method comprising administering to the subject a pharmaceutically effective amount of a SK1 inhibitor in combination with the immune checkpoint inhibitor, wherein the immune checkpoint inhibitor is an antibody and wherein the SK1 inhibitor is a small molecule, and wherein the SK1 inhibitor is SK1-I.

2. A method of treating melanoma or colon cancer in a subject in need thereof comprising administering to the subject a therapeutically effective combination of an immune checkpoint inhibitor with a SK1 inhibitor, wherein administration of the combination results in enhanced therapeutic efficacy relative to the administration of the immune checkpoint inhibitor alone, wherein the immune checkpoint inhibitor is an antibody and wherein the SK1 inhibitor is a small molecule, and wherein the SK1 inhibitor is SK1-I and the immune checkpoint inhibitor is pembrolizumab.

3. The method of claim 1 wherein the subject suffers from a melanoma.

4. The method of claim 1 wherein the subject suffers from a melanoma resistant to BRAF inhibitors.

5. The method of claim 1 wherein the subject suffers from a melanoma with elevated plasma dehydrogenase (LDH).

6. The method of claim 1 wherein the subject suffers from a cancer characterized by a low tumor infiltration of CD8+ T cells.

7. The method of claim 1 wherein the immune checkpoint inhibitor is an antibody selected from the group consisting of anti-CTLA4 antibodies, anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-PD-L2 antibodies anti-TIM-3 antibodies, anti-LAG3 antibodies, anti-B7H3 antibodies, anti-B7H4 antibodies, anti-BTLA antibodies, and anti-B7H6 antibodies.

Assignees

• Inst Nat Sante Rech Med
• Univ Toulouse Iii—Paul Sabatier
• Ct Hospitalier Universitaire Toulouse
• Inserm Institut National De La Santeet De La Rech Medicale

Inventors

• Levade Thierry
• Meyer Nicolas
• Colacios Viatgé Céline
• Imbert Caroline
• Andrieu-Abadie Nathalie
• Segui Bruno

Classifications

• G01N33/575

  for cancer · CPC title

• G01N2333/70517

  CD8 · CPC title

• A61K2039/507

  Comprising a combination of two or more separate antibodies · CPC title

• G01N33/56972

  White blood cells · CPC title

• A61K2039/505

  comprising antibodies · CPC title